Literature DB >> 19471850

Recent developments in multiple system atrophy.

Gregor K Wenning1, Nadia Stefanova.   

Abstract

Multiple system atrophy (MSA) is a rare late onset neurodegenerative disorder which presents with autonomic failure and a complicated motor syndrome including atypical parkinsonism, ataxia and pyramidal signs. MSA is a glial alpha-synucleinopathy with rapid progression and currently poor therapeutic management. This paper reviews the clinical features, natural history and novel diagnostic criteria for MSA as well as contemporary knowledge on pathogenesis based on evidence from neuropathological studies and experimental models. An outline of the rationale for managing symptomatic deterioration in MSA is provided together with a summary of novel experimental therapeutic approaches to decrease disease progression.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19471850     DOI: 10.1007/s00415-009-5173-8

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  216 in total

1.  No mutation in the entire coding region of the alpha-synuclein gene in pathologically confirmed cases of multiple system atrophy.

Authors:  T Ozawa; H Takano; O Onodera; H Kobayashi; T Ikeuchi; R Koide; K Okuizumi; T Shimohata; K Wakabayashi; H Takahashi; S Tsuji
Journal:  Neurosci Lett       Date:  1999-07-30       Impact factor: 3.046

Review 2.  Epidemiological evidence on multiple system atrophy.

Authors:  N Vanacore
Journal:  J Neural Transm (Vienna)       Date:  2005-12       Impact factor: 3.575

3.  Red flags for multiple system atrophy.

Authors:  Martin Köllensperger; Felix Geser; Klaus Seppi; Michaela Stampfer-Kountchev; Martin Sawires; Christoph Scherfler; Sylvia Boesch; Joerg Mueller; Vasiliki Koukouni; Niall Quinn; Maria Teresa Pellecchia; Paolo Barone; Nicole Schimke; Richard Dodel; Wolfgang Oertel; Erik Dupont; Karen Østergaard; Christine Daniels; Günther Deuschl; Tanya Gurevich; Nir Giladi; Miguel Coelho; Cristina Sampaio; Christer Nilsson; Håkan Widner; Francesca Del Sorbo; Alberto Albanese; Adriana Cardozo; Eduardo Tolosa; Michael Abele; Thomas Klockgether; Christoph Kamm; Thomas Gasser; Ruth Djaldetti; Carlo Colosimo; Giuseppe Meco; Anette Schrag; Werner Poewe; Gregor K Wenning
Journal:  Mov Disord       Date:  2008-06-15       Impact factor: 10.338

4.  Hyperphosphorylation and insolubility of alpha-synuclein in transgenic mouse oligodendrocytes.

Authors:  Philipp J Kahle; Manuela Neumann; Laurence Ozmen; Veronika Muller; Helmut Jacobsen; Will Spooren; Babette Fuss; Barbara Mallon; Wendy B Macklin; Hideo Fujiwara; Masato Hasegawa; Takeshi Iwatsubo; Hans A Kretzschmar; Christian Haass
Journal:  EMBO Rep       Date:  2002-05-24       Impact factor: 8.807

5.  Clinical features and natural history of multiple system atrophy. An analysis of 100 cases.

Authors:  G K Wenning; Y Ben Shlomo; M Magalhães; S E Daniel; N P Quinn
Journal:  Brain       Date:  1994-08       Impact factor: 13.501

6.  Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice.

Authors:  Shan Zhu; Irina G Stavrovskaya; Martin Drozda; Betty Y S Kim; Victor Ona; Mingwei Li; Satinder Sarang; Allen S Liu; Dean M Hartley; Du Chu Wu; Steven Gullans; Robert J Ferrante; Serge Przedborski; Bruce S Kristal; Robert M Friedlander
Journal:  Nature       Date:  2002-05-02       Impact factor: 49.962

Review 7.  The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes.

Authors:  S Braune
Journal:  Clin Auton Res       Date:  2001-12       Impact factor: 4.435

8.  Alpha-1-antichymotrypsin gene polymorphism and susceptibility to multiple system atrophy (MSA).

Authors:  Yoshiko Furiya; Makito Hirano; Norio Kurumatani; Takuya Nakamuro; Ryusuke Matsumura; Naonobu Futamura; Satoshi Ueno
Journal:  Brain Res Mol Brain Res       Date:  2005-08-18

Review 9.  Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].

Authors:  M B Youdim; M Weinstock
Journal:  Cell Mol Neurobiol       Date:  2001-12       Impact factor: 5.046

10.  Usefulness of combined fractional anisotropy and apparent diffusion coefficient values for detection of involvement in multiple system atrophy.

Authors:  Mizuki Ito; Hirohisa Watanabe; Yoshinari Kawai; Naoki Atsuta; Fumiaki Tanaka; Shinji Naganawa; Hiroshi Fukatsu; Gen Sobue
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-03-12       Impact factor: 10.154

View more
  30 in total

1.  Autonomic symptoms in idiopathic REM behavior disorder: a multicentre case-control study.

Authors:  Luigi Ferini-Strambi; Wolfgang Oertel; Yves Dauvilliers; Ronald B Postuma; Sara Marelli; Alex Iranzo; Isabelle Arnulf; Birgit Högl; Högl Birgit; Raffaele Manni; Tomoyuki Miyamoto; Maria-Livia Fantini; Monica Puligheddu; Poul Jennum; Karel Sonka; Joan Santamaria; Marco Zucconi; Paola M V Rancoita; Smeranda Leu-Semenescu; Birgit Frauscher; Michele Terzaghi; Masayuki Miyamoto; Marcus Unger; Karin Stiasny-Kolster; Alex Desautels; Christina Wolfson; Amélie Pelletier; Jacques Montplaisir
Journal:  J Neurol       Date:  2014-04-01       Impact factor: 4.849

Review 2.  Treatment of multiple system atrophy - the past, present and future.

Authors:  Haiyan Yu; Xiaoling Yuan; Lifeng Liu; Tian Wang; Dianrong Gong
Journal:  Am J Clin Exp Immunol       Date:  2018-10-05

Review 3.  Management approaches to hypertension in autonomic failure.

Authors:  Amy C Arnold; Italo Biaggioni
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-09       Impact factor: 2.894

Review 4.  Neuromuscular and systemic presentations in adults: diagnoses beyond MERRF and MELAS.

Authors:  Bruce H Cohen
Journal:  Neurotherapeutics       Date:  2013-04       Impact factor: 7.620

Review 5.  Fragile X-associated tremor/ataxia syndrome: phenotypic comparisons with other movement disorders.

Authors:  Erin E Robertson; Deborah A Hall; Andrew R McAsey; Joan A O'Keefe
Journal:  Clin Neuropsychol       Date:  2016-08       Impact factor: 3.535

Review 6.  Synucleinopathies: common features and hippocampal manifestations.

Authors:  Weiwei Yang; Shun Yu
Journal:  Cell Mol Life Sci       Date:  2016-11-08       Impact factor: 9.261

7.  The Diagnosis and Natural History of Multiple System Atrophy, Cerebellar Type.

Authors:  David J Lin; Katherine L Hermann; Jeremy D Schmahmann
Journal:  Cerebellum       Date:  2016-12       Impact factor: 3.847

8.  Evaluation of autonomic functions of patients with multiple system atrophy and Parkinson's disease by head-up tilt test.

Authors:  Chikako Watano; Yuri Shiota; Keiichi Onoda; Abdullah Md Sheikh; Seiji Mishima; Eri Nitta; Shozo Yano; Shuhei Yamaguchi; Atsushi Nagai
Journal:  J Neural Transm (Vienna)       Date:  2017-11-28       Impact factor: 3.575

9.  SUMO-1 is associated with a subset of lysosomes in glial protein aggregate diseases.

Authors:  Mathew B Wong; Jacob Goodwin; Anwar Norazit; Adrian C B Meedeniya; Christiane Richter-Landsberg; Wei Ping Gai; Dean L Pountney
Journal:  Neurotox Res       Date:  2012-11-15       Impact factor: 3.911

10.  Targeted overexpression of human alpha-synuclein in oligodendroglia induces lesions linked to MSA-like progressive autonomic failure.

Authors:  Sylvia Stemberger; Werner Poewe; Gregor K Wenning; Nadia Stefanova
Journal:  Exp Neurol       Date:  2010-05-21       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.